| First Author | Cleveland SM | Year | 2014 |
| Journal | Exp Hematol | Volume | 42 |
| Issue | 7 | Pages | 581-93.e5 |
| PubMed ID | 24792354 | Mgi Jnum | J:214004 |
| Mgi Id | MGI:5587859 | Doi | 10.1016/j.exphem.2014.04.010 |
| Citation | Cleveland SM, et al. (2014) LMO2 induces T-cell leukemia with epigenetic deregulation of CD4. Exp Hematol 42(7):581-93.e5 |
| abstractText | In this study, we present a remarkable clonal cell line, 32080, derived from a CD2-Lmo2- transgenic T-cell leukemia with differentiation arrest at the transition from the intermediate single positive to double positive stages of T-cell development. We observed that 32080 cells had a striking variegated pattern in CD4 expression. There was cell-to-cell variability, with some cells expressing no CD4 and others expressing high CD4. The two populations were isogenic and yet differed in their rates of apoptosis and sensitivity to glucocorticoid. We sorted the 32080 line for CD4-positive or CD4-negative cells and observed them in culture. After 1 week, both sorted populations showed variegated CD4 expression, like the parental line, showing that the two populations could interconvert. We determined that cell replication was necessary to transit from CD4(+) to CD4(-) and CD4(-) to CD4(+). Lmo2 knockdown decreased CD4 expression, while inhibition of intracellular NOTCH1 or histone deacetylase activity induced CD4 expression. Enforced expression of RUNX1 repressed CD4 expression. We analyzed the CD4 locus by Histone 3 chromatin immunoprecipitation and found silencing marks in the CD4(-) cells and activating marks in the CD4(+) population. The 32080 cell line is a striking model of intermediate single positive to double positive T-cell plasticity and invokes a novel mechanism for LMO2's oncogenic functions. |
